{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema:ojemda:0 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema%3Aojemda%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.006335,
    "timestamp_received": "2026-09-25T06:02:40.163194+00:00Z",
    "timestamp_returned": "2026-09-25T06:02:40.169529+00:00Z",
    "trace_id": "e827c893-2431-4875-8677-c8caebce9710"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "ind:ema:ojemda:0",
      "type": "Indication",
      "description": "Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2026-08-02:0",
          "type": "Contribution",
          "description": "Initial curation of into moalmanac-db",
          "date": "2026-08-02",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2026-04-20:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2026-04-20",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:ojemda",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Ojemda (tovorafenib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Ipsen Pharma. Ojemda (tovorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf. Revised May 2026. Accessed August 2, 2026.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/ojemda"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Ipsen Pharma",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Ojemda",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "tovorafenib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2026-05-11",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": "EMEA/H/C/006140",
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2026-05-11",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        }
      ]
    }
  ]
}